Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics?

Viking Therapeutics has $706M in cash/equivalents and TTM operating expenses of $393M; its lead candidate VK2735 produced positive phase 2 results and is in two phase 3 programs with the oral formulation entering phase 3 in Q3 2026 — success could materially re-rate the stock but commercialization faces heavy competition from Novo Nordisk and Eli Lilly. Bitcoin benefits from substantial ETF-driven demand (about $614M in U.S. spot-ETF inflows on March 4 and roughly $57B cumulative inflows) and supply-side constraints (quadrennial halvings), supporting further appreciation but with high volatility. Author's view: Bitcoin is the preferable $1,500 allocation for most investors due to fewer single-catalyst execution risks, whereas Viking offers higher upside if a chain of clinical and commercial outcomes all go right.

Analysis

Viking sits on a binary beta: phase-3 readouts and payer/market-access dynamics will reprice equity by multiples, but the market is under-discounting two second-order levers — oral formulation uptake segmentation (primary care vs specialist-managed injectables) and IP/CMC complexity that raises switching costs for incumbents. If Viking can show differentiated tolerability or adherence with the oral form, commercial penetration curves could follow a distinct S-curve (0→5→15% share) even in a crowded GLP-1 market, making a small current market cap translate into 3x+ revenue upside over 3–5 years. Conversely, the more mundane path — marginal non-inferiority with squeezed net pricing — would cause valuation compression as incumbents defend formulary access via rebates and bundle contracting.

Bitcoin’s pathway is less binary but more flow-driven: ETF issuers and structural investors create persistent marginal bid that compounds around halving cadence and liquidity windows, so price moves will be highly sensitive to large institutional rebalancing days and macro volatility spikes. The key tail risks are regulatory clampdowns on custody/ETF mechanics, or a liquidity-driven unwind where correlation to risk assets transiently spikes; these compressions are rapid (days–weeks) but often recover over quarters. For portfolio construction, treat Viking as event-driven asymmetric beta and Bitcoin exposure as regime-sensitive allocation that requires active volatility sizing and liquidity-aware instruments.

The overlooked consensus gap: markets are pricing both as either “binary gamble” (Viking) or “macro play” (Bitcoin), missing a plausible middle path where Viking is an M&A arbitrage candidate if phase-2 signals replicate and a large incumbent prefers acquisition over a prolonged price war; that outcome materially raises odds of a >3x exit within 12–24 months and is underpriced today.

Key Decisions for Investors

• VKTX — Buy a defined-risk bullish calendar call spread (buy Jan-2027 20% OTM calls, sell Jan-2026 nearer-dated calls) sized 1–2% of NAV. Rationale: captures upside if Phase-3 and commercial clarity arrive over 12–18 months; max loss = premium paid (~100% of allocation to trade), upside asymmetry 3x–10x if clinical/commercial differentiation occurs.
• VKTX/NVO pair — Long VKTX 1% NAV / Short NVO 0.25% NAV as a hedge against class-wide GLP-1 moves (12–24 month horizon). Rationale: isolates idiosyncratic clinical/commercial upside while partially hedging broader category-level flows; expect positive skew if Viking demonstrates oral adherence advantage or triggers M&A interest.
• NDAQ — Buy Nasdaq (NDAQ) 6–12 month call or 2–3% equity position to capture continued spot-Bitcoin ETF fee and listing flow tailwinds. Rationale: ETF AUM growth is recurring revenue for exchanges; target +25–40% upside if ETF flows continue, with downside capped to equity-market drawdowns (~15–25% in stress).
• Risk management — Keep VKTX exposure concentrated to <=3% total portfolio and size Bitcoin-related proxy exposure (NDAQ or spot ETF) to 1–3% for diversified portfolios; use trailing stops and reduce VKTX option exposure 6–8 weeks pre-readout to avoid event-time gamma burn.